BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

被引:2291
作者
Reig, Maria [1 ,2 ]
Forner, Alejandro [1 ,2 ]
Rimola, Jordi [3 ]
Ferrer-Fabrega, Joana [4 ]
Burrel, Marta [5 ]
Garcia-Criado, Angeles [3 ]
Kelley, Robin K. [6 ]
Galle, Peter R. [7 ]
Mazzaferro, Vincenzo [8 ,9 ]
Salem, Riad [10 ]
Sangro, Bruno [2 ,11 ]
Singal, Amit G. [12 ]
Vogel, Arndt [13 ]
Fuster, Josep [2 ,4 ]
Ayuso, Carmen [2 ,3 ]
Bruix, Jordi [1 ,2 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, BCLC Grp,Liver Unit,ICMDM, Barcelona, Spain
[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, CDI, BCLC Grp,Radiol Dept, Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, BCLC Grp,Surg Dept,ICMDM, Barcelona, Spain
[5] Univ Barcelona, BCLC Grp, Vasc Dept, CDI,Hosp Clin Barcelona,Barcelona Univ, Barcelona, Spain
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[7] Mainz Univ, Dept Internal Med, Med Ctr, Mainz, Germany
[8] Univ Milan, Dept Oncol, Milan, Italy
[9] Fdn IRCCS Ist Nazl Tumori, HPB Surg & Liver Transplantat, Milan, Italy
[10] Northwestern Univ, Dept Radiol, Sect Intervent Radiol, Chicago, IL USA
[11] Clin Univ Navarra, Liver Unit, Pamplona, Spain
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
[13] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
关键词
HCC; survival; BCLC; ablation; surgery; liver transplantation TACE; TARE; systemic treatment; ALBI score; AFP; RANDOMIZED CONTROLLED-TRIAL; UNRESECTABLE HEPATOCELLULAR-CARCINOMA; CLINICAL DECISION-MAKING; OPEN LIVER RESECTION; RADIOFREQUENCY ABLATION; TRANSARTERIAL CHEMOEMBOLIZATION; ALPHA-FETOPROTEIN; SURGICAL RESECTION; HEPATIC RESECTION; PORTAL-HYPERTENSION;
D O I
10.1016/j.jhep.2021.11.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:681 / 693
页数:13
相关论文
共 127 条
  • [1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 54 - 63
  • [2] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Kudo, Masatoshi
    Lau, George
    Kelley, Robin Kate
    Furuse, Junji
    Sukeepaisarnjaroen, Wattana
    Kang, Yoon-Koo
    Dao, Tu V.
    De Toni, Enrico N.
    Rimassa, Lorenza
    Breder, Valeriy Vladimirovich
    Vasilyev, Alexander
    Heurgue, Alexandra
    Tam, Vincent
    Mody, Kabir
    Thungappa, Satheesh Chiradoni
    He, Philip
    Negro, Alejandra
    Sangro, Bruno
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    Baffy, Gyorgy
    Bosch, Jaume
    [J]. JOURNAL OF HEPATOLOGY, 2022, 76 (02) : 458 - 463
  • [4] Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis
    Berardi, Giammauro
    Morise, Zenichi
    Sposito, Carlo
    Igarashi, Kazuharu
    Panetta, Valentina
    Simonelli, Ilaria
    Kim, Sungho
    Goh, Brian K. P.
    Kubo, Shoji
    Tanaka, Shogo
    Takeda, Yutaka
    Ettorre, Giuseppe Maria
    Wilson, Gregory C.
    Cimino, Matteo
    Chan, Chung-Yip
    Torzilli, Guido
    Cheung, Tan To
    Kaneko, Hironori
    Mazzaferro, Vincenzo
    Geller, David A.
    Han, Ho-Seong
    Kanazawa, Akishige
    Wakabayashi, Go
    Troisi, Roberto Ivan
    [J]. JOURNAL OF HEPATOLOGY, 2020, 72 (01) : 75 - 84
  • [5] Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis
    Berzigotti, Annalisa
    Reig, Maria
    Abraldes, Juan G.
    Bosch, Jaime
    Bruix, Jordi
    [J]. HEPATOLOGY, 2015, 61 (02) : 526 - 536
  • [6] Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
    Brown, Karen T.
    Do, Richard K.
    Gonen, Mithat
    Covey, Anne M.
    Getrajdman, George I.
    Sofocleous, Constantinos T.
    Jarnagin, William R.
    D'Angelica, Michael I.
    Allen, Peter J.
    Erinjeri, Joseph P.
    Brody, Lynn A.
    O'Neill, Gerald P.
    Johnson, Kristian N.
    Garcia, Alessandra R.
    Beattie, Christopher
    Zhao, Binsheng
    Solomon, Stephen B.
    Schwartz, Lawrence H.
    DeMatteo, Ronald
    Abou-Alfa, Ghassan K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) : 2046 - +
  • [7] Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure
    Bruix, J
    Castells, A
    Bosch, J
    Feu, F
    Fuster, J
    GarciaPagan, JC
    Visa, J
    Bru, C
    Rodes, J
    [J]. GASTROENTEROLOGY, 1996, 111 (04) : 1018 - 1022
  • [8] Systemic treatment of hepatocellular carcinoma: An EASL position paper
    Bruix, Jordi
    Chan, Stephen L.
    Galle, Peter R.
    Rimassa, Lorenza
    Sangro, Bruno
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 (04) : 960 - 974
  • [10] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Bruix, Jordi
    Qin, Shukui
    Merle, Philippe
    Granito, Alessandro
    Huang, Yi-Hsiang
    Bodoky, Gyrogy
    Pracht, Marc
    Yokosuka, Osamu
    Rosmorduc, Olivier
    Breder, Valeriy
    Gerolami, Rene
    Masi, Gianluca
    Ross, Paul J.
    Song, Tianqiang
    Bronowicki, Jean-Pierre
    Ollivier-Hourmand, Isabelle
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Llovet, Josep M.
    Finn, Richard S.
    LeBerre, Marie-Aude
    Baumhauer, Annette
    Meinhardt, Gerold
    Han, Guohong
    [J]. LANCET, 2017, 389 (10064) : 56 - 66